Gilead Sciences (GILD) EV to EBITDA (2009 - 2026)
Gilead Sciences (GILD) EV to EBITDA (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EV to EBITDA |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
8.71 Mn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
30.10 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
13.43 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
25.62 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-52.99 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
16.72 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
14.70 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-7.64 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
14.50 |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
6.37 |
| Date | Value |
|---|
| Jun 5, 2026 |
14.70 |
| Jun 4, 2026 |
14.73 |
| Jun 3, 2026 |
14.70 |
| Jun 2, 2026 |
14.54 |
| Jun 1, 2026 |
14.99 |
| May 29, 2026 |
15.35 |
| May 28, 2026 |
15.57 |
| May 27, 2026 |
15.27 |
| May 26, 2026 |
15.28 |
| May 22, 2026 |
15.35 |
| May 21, 2026 |
14.88 |
| May 20, 2026 |
14.94 |
| May 19, 2026 |
14.89 |
| May 18, 2026 |
14.79 |
| May 15, 2026 |
14.77 |
| May 14, 2026 |
15.07 |
| May 13, 2026 |
15.19 |
| May 12, 2026 |
15.41 |
| May 11, 2026 |
15.24 |
| May 8, 2026 |
14.98 |
